Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing life-saving medicines, has announced its participation in the upcoming JonesTrading Virtual Precision Medicine Symposium.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing life-saving medicines, has announced its participation in the upcoming JonesTrading Virtual Precision Medicine Symposium. Mike Andriole, CEO, and Tom Riga, Chief Operating and Commercial Officer, will engage in a fireside chat on Monday, February 3, 2025, at 11:00 a.m. ET.
The presentation will be accessible via audio webcast through the Investor Relations section of Chimerix's website at ir.chimerix.com. The recording will remain available for approximately 90 days following the event.
Details
News Market Reaction – CMRX
The recorded move for CMRX in the trading session of this news was +0.98%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer, will participate in a fireside chat at the JonesTrading Virtual Precision Medicine Symposium on Monday, February 3, 2025 at 11:00 a.m. ET.
An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone, is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
INVESTOR CONTACT:
Will O’Connor
Stern Investor Relations
will.oconnor@sternir.com
MEDIA CONTACT:
Dana Davis
Steelwire
dana@steelwire.co
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.